In re Alberto-Culver Company Shareholder Litigation
|Court:||Delaware Court of Chancery|
|Case Number:||Consolidated C.A. No. 5873-VCS|
|Judge:||Vice Chancellor Leo Strine|
|Case Contacts:||Mark Lebovitch, Brett M. Middleton|
On October 5, 2010, BLB&G filed a class action complaint (the "Complaint") in the Delaware Court of Chancery on behalf Laborers Local 235 Benefit Funds and similarly situated public shareholders of beauty products company Alberto-Culver Co. ("Alberto-Culver" or the "Company") challenging the terms of a proposed sale of the Company to Unilever (the "Proposed Transaction"). Among other things, the Complaint alleged that the Alberto-Culver board of directors (the "Board") improperly structured the Proposed Transaction to favor its preferred bidder, Unilever, and dissuade other interested parties from bidding for the Company in order to further the interests of Alberto-Culver's patriarch and his family. The agreement between Alberto-Culver and Unilever forbade the Board from taking any steps to maximize shareholder value by restricting its ability to contact potential bidders and limiting the information it could provide to interested third parties. In addition, the agreement provided Unilever unlimited matching rights - preclusive privileges that deter potential bidders from expending times and resources on an offer when it could be summarily "matched" by a favored buyer.
On October 20, 2010, BLB&G filed an amended complaint (the "Amended Complaint") that added claims relating to the wholly inadequate disclosure made by the Company in its Preliminary Proxy Statement relating to the Proposed Transaction filed on October 15, 2010 (the "Proxy"). In addition to numerous other shortcomings, the Proxy failed to adequately describe the Board's decision to negotiate exclusively with Unilever.
After an expedited discovery that included the review of thousands of pages of documents and numerous depositions in a matter of weeks, BLB&G filed a motion to enjoin the Proposed Transaction on November 23, 2010.
On November 29, 2010, the parties agreed to settle all of the outstanding claims in the lawsuit. As part of the settlement Alberto-Culver agreed to:
1) eliminate the matching rights it had granted to Unilever;
2) lower any break-up fee the Company may be obliged to pay by $25 million to $100 million; and
3) be prepared to promptly provide any superior bidder with the same confidential documents that had been shared with Unilever.
In addition, Alberto-Culver agreed to amend the Proxy to provide shareholders with substantially more information about the Proposed Transaction and process, and to postpone a scheduled shareholder vote on the Proposed Transaction until December 17, 2010, in order to give shareholders adequate time to analyze the transaction, and any potential suitor time to bid for the Company.
The Court preliminarily approved the settlement and BLBG provided notice to the class. Subsequently, on January 24, 2011 BLBG submitted Plaintiffs' papers in support of final approval of the proposed settlement and the Court approved the settlement on February 21, 2011.
Other Cases of Interest
- Twenty-First Century Fox, Inc.
Delaware Chancery Court Max W. Berger, Mark Lebovitch, David Wales, Rebecca E. Boon
- Sanchez Energy
Delaware Court of Chancery David Wales, Mark Lebovitch, Christopher J. Orrico, Alla Zayenchik
- Allergan, Inc. (Proxy Violation)
Central District of California Mark Lebovitch, Jeremy P. Robinson, Michael D. Blatchley, Richard D. Gluck, Edward G. Timlin
- Suprema Specialties, Inc.
District of New Jersey Max W. Berger, Mark Lebovitch, Rochelle Feder Hansen
- Merrill Lynch & Co., Inc. (Bond Action)
Southern District of New York Max W. Berger, Mark Lebovitch, Kurt Hunciker
- Lumber Liquidators Holdings, Inc.
Eastern District of Virginia Gerald H. Silk, Avi Josefson, David R. Stickney, Brett M. Middleton, Scott R. Foglietta
- Kinder Morgan Energy Partnership, L.P.
Delaware Court of Chancery Mark Lebovitch, David Wales, Adam Hollander
- El Paso Corporation
Delaware Court of Chancery Mark Lebovitch
- Dura Pharmaceuticals, Inc.
Southern District of California David R. Stickney, Brett M. Middleton